2024 World Conference on Lung Cancer (WCLC) - Posters-P3.13D.02 DLL3 Expression in Early-Stage SCLC: Comparative Analysis of IHC and mRNA ISH in Tumor and Lymph Nodes

P3.13D.02 DLL3 Expression in Early-Stage SCLC: Comparative Analysis of IHC and mRNA ISH in Tumor and Lymph Nodes

Pdf Summary

The study assessed DLL3 expression in early-stage small cell lung cancer (SCLC) using immunohistochemistry (IHC) and mRNA in situ hybridization (ISH) methods. DLL3, a potential target for new therapies, is frequently overexpressed in SCLC. The study included 248 resected samples from patients between 1978 and 2013, correlating DLL3 expression between primary tumors and metastatic lymph nodes.<br /><br />Findings revealed that DLL3 positivity was observed in 58% and 87% of the samples using IHC and mRNA ISH, respectively. In metastatic lymph nodes, DLL3 was 69% positive by IHC and 100% by mRNA ISH. A strong correlation was noted between results from IHC and mRNA ISH assays, and between tumor and lymph node metastasis DLL3 positivity (p-values of 0.024 and 0.047).<br /><br />Survival analysis, available for 137 patients, indicated a non-significant trend towards better median overall survival for patients with positive DLL3 expression. The median overall survival with IHC score 1 was 27.1 months, compared to 21.0 months for score 0 (p0.893). For mRNA ISH, the mOS was 38.9 months for score 1 versus 18.9 months for score 0 (p0.221).<br /><br />The study concluded that DLL3 is expressed frequently in early-stage SCLC and its expression methods show significant correlation in both tumors and metastases. However, there was no significant correlation between DLL3 positivity and patient characteristics or survival outcomes. The researchers recommend further studies to explore DLL3's role in improving SCLC treatment approaches.

Asset Subtitle

May-Lucie Meyer

Meta Tag

Speaker May-Lucie Meyer

Topic SCLC & Neuroendocrine Tumors

Keywords

DLL3 expression

small cell lung cancer

immunohistochemistry

mRNA in situ hybridization

metastatic lymph nodes

survival analysis

tumor correlation

therapeutic target

early-stage SCLC

treatment approaches